ArticleFrontiers in medicine2021
Case Report: Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination.
Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- SARS-CoV-2 vaccine-related cutaneous manifestations: a systematic review.International journal of dermatology · 2022Pooled it
- Pityriasis following COVID-19 vaccinations: a systematic review.Dermatology reports · 2024Article
- Article
- Pityriasis Rosea and Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination: A Narrative Review.Clinical, cosmetic and investigational dermatology · 2024Review
- Review
- A Review of Pityriasis Rosea in Relation to SARS-CoV-2/COVID-19 Infection and Vaccination.Cureus · 2023Review
- Pityriasis rosea and pityriasis rosea-like eruption after anti-SARS-CoV-2 vaccination: a report of five cases and review of the literature.Dermatology reports · 2023Article
- Pathobiology of Cutaneous Manifestations Associated with COVID-19 and Their Management.Viruses · 2022Review
- Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review.Microorganisms · 2022Review
- Article
- Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature.Clinical, cosmetic and investigational dermatology · 2022Review
- Management of coronavirus disease 2019 vaccine-induced cutaneous complications: A comprehensive literature review.Journal of family & community medicineReview
- Vesiculobullous and Other Cutaneous Manifestations of COVID-19 Vaccines: a Scoping and Narrative Review.Journal of cutaneous medicine and surgeryArticle
- Cutaneous Adverse Drug Reactions (CADRs) to COVID19 Vaccines: A Case Series.Indian dermatology online journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccination is one of the cornerstones in the efforts towards ending the coronavirus disease 2019 (COVID-19) pandemic. However, several adverse effects of COVID-19 vaccination have been identified. Pityriasis rosea (PR)-like eruption is a rare cutaneous complication of immunization. To the best of our knowledge, there have been no reports of PR-like eruptions following inoculation with Oxford/AstraZeneca ChAdOx1 nCoV-19 (AZD1222) vaccine. Here, we described a case of PR-like eruption that developed 14 days after Oxford/AstraZeneca vaccination in a 52-year-old Thai woman with glioblastoma. Treatment with topical 0.1% triamcinolone acetonide twice per day showed partial response after seven days. Despite this rare complication, our report highlights that the presence of PR-like eruption is not a contraindication for subsequent vaccinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.